Apyx Shares Rise 7% After FDA Clearance
19 July 2022 - 12:39AM
Dow Jones News
By Dean Seal
Shares of Apyx Medical Corp. climbed 7% to $8.03 in early
trading Monday after the company said it received regulatory
clearance for its treatment Renuvion.
The medical technology company said the Food and Drug
Administration cleared the proprietary helium plasma and
radiofrequency technology for use in procedures to improve the
appearance of loose skin on the neck and chin.
Renuvion is a minimally-invasive procedure that directly treats
collagen fibers in the neck and chin and addresses the root cause
of laxity, the Clearwater, Fla.-based company said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
July 18, 2022 10:24 ET (14:24 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Apyx Medical (NASDAQ:APYX)
Historical Stock Chart
From May 2023 to Jun 2023
Apyx Medical (NASDAQ:APYX)
Historical Stock Chart
From Jun 2022 to Jun 2023
